General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | 0 | N/A | N/A | N/A |
2024-03-07 | 2023-12 | 0 | N/A | N/A | N/A |
2023-11-02 | 2023-09 | 0 | N/A | N/A | N/A |
2023-08-03 | 2023-06 | 0 | N/A | N/A | N/A |
2023-05-04 | 2023-03 | 0 | N/A | N/A | N/A |
2023-03-09 | 2022-12 | 0 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2018-10-21 | Baird | Upgrade | Neutral | Neutral |
2018-06-25 | Baird | Upgrade | Neutral | Neutral |
2018-06-24 | JP Morgan | Downgrade | Neutral | Underweight |
2016-10-06 | JP Morgan | Downgrade | Overweight | Neutral |
2016-08-18 | BTIG | Upgrade | Neutral | |
2016-08-04 | JP Morgan | Upgrade | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2019-04-16 | 22NW, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2023-12-27 | ANDERSEN ERIC D | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2019-07-15 | ARYEH JASON M | Beneficial Owner of more than 10% of a Class of Security | 3.80K | Purchase |
2023-08-10 | CROCKER GARY L | President | 0.00 | Purchase |
2017-05-11 | DRUMMOND DARYL C | Officer | 0.00 | Sale |
2019-07-01 | JFL CAPITAL MANAGEMENT, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Newtyn Management, Llc | 1.87M | 23.05M | 13.08% |
2023-06-29 | Western Standard, LLC | 1.67M | 20.57M | 11.68% |
2023-06-29 | Blackrock Inc. | 676.29K | 8.32M | 4.72% |
2023-06-29 | Vanguard Group Inc | 556.80K | 6.85M | 3.89% |
2023-06-29 | Madison Avenue Partners, LP | 553.09K | 6.80M | 3.86% |
2023-06-29 | Dimensional Fund Advisors LP | 459.96K | 5.66M | 3.21% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 286.03K | 3.52M | 2.00% |
2023-08-30 | iShares Russell 2000 ETF | 218.88K | 2.67M | 1.53% |
2023-06-29 | Vanguard Extended Market Index Fund | 198.20K | 2.44M | 1.38% |
2023-07-30 | DFA U.S. Micro Cap Series | 148.85K | 1.79M | 1.04% |
2023-07-30 | DFA U.S. Small Cap Series | 115.24K | 1.38M | 0.80% |
2023-07-30 | Fidelity Small Cap Index Fund | 99.81K | 1.20M | 0.70% |
Dividend | Date |
---|---|
15.1 | 2024-05-20 |
15.1 | 2024-05-09 |
0.5 | 2019-12-13 |
1.49668 | 2019-09-06 |
1.05521 | 2017-05-30 |
Split | Date |
---|---|
1271 : 1000 | 2019-09-06 |
1 : 10 | 2017-09-06 |
US)
15.000
14.880
+7.22%
-0.80%
By Sabela Ojea
Merrimack Pharmaceuticals said it will receive a $225 million milestone payment from Ipsen after the U.S. Food and Drug Administration approved the supplemental new drug application for its pancreatic cancer treatment Onivydee.
The biopharmaceutical company on Tuesday said the payment is due on or before March 29.
The company has received several payments from Ipsen in the past, including a $575 million payment in 2017.
Sooon $HYLN
Sold my calls hope my puts play out next week